A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study)

Study Identifier
P19-831
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Recruitment Complete
Sign up for trial alerts

Study Details

Medical Condition
  • Blood Cancer - Acute Myeloid Leukemia (AML)
  • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years

    Protocol Summary

    This study will describe the safety and effectiveness of venetoclax in AML patients in routine clinical practice in Israel. The decision to treat with venetoclax is made by the physician prior to any decision regarding participation in this study.

    Study Locations

    Location
    Status
    Location
    Meir Medical Center /ID# 213352
    Kfar Saba, Central District, Israel, 4428164
    Status
    Not applicable
    Location
    Assuta Tel Aviv Medical Center /ID# 213371
    Tel Aviv, Central District, Israel, 6971028
    Status
    Not applicable
    Location
    HaEmek Medical Center /ID# 213370
    Afula, Haifa District, Israel, 1834111
    Status
    Not applicable
    Location
    Shaare Zedek Medical Center /ID# 228016
    Jerusalem, Jerusalem, Israel, 91031
    Status
    Not applicable
    Location
    Hadassah /ID# 213356
    Jerusalem, Jerusalem, Israel, 91120
    Status
    Not applicable
    Location
    ZIV Medical Center /ID# 229211
    Safed, Northern District, Israel, 13100
    Status
    Not applicable
    Showing {first} - {last} of {total} Results